- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Leslie on Remaining Questions to Address in MCL
July 11th 2020, 6:18pm
PER® Annual Live Medical Crossfire: Hematologic Malignancies
Lori Leslie, MD, discusses key questions to address with future research efforts in mantle cell lymphoma.
Postow Presents Progress Made in Melanoma
July 10th 2020, 9:47pm
Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation during the 2020 ASCO Direct Highlights webcast.
Singal Speaks to ASCO Highlights in Rapidly Evolving HCC Paradigm
July 10th 2020, 6:29pm
The treatment landscape of advanced hepatocellular carcinoma has been subject to rapid development in the last few years, says Amit G. Singal, MD, MS.
ASCO 2020 Heralds a Handful of Influential Data Across Breast Cancer Settings
July 10th 2020, 5:30pm
The 2020 ASCO Virtual Scientific Program delivered a number of important updates to the field of breast cancer, explained Joyce A. O'Shaughnessy, MD.
Dr. Kim on Efficacy and Next Steps With Regorafenib/Nivolumab Combo in CRC
July 3rd 2020, 3:45pm
ESMO Gastrointestinal Cancers Congress
Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.
Later-Line Infigratinib Outperforms Standard Chemotherapy in Cholangiocarcinoma
July 3rd 2020, 3:15pm
ESMO Gastrointestinal Cancers Congress
Infigratinib conferred a clinically meaningful progression-free survival and overall response rate benefit when administered as a third- and later-line treatment for patients with FGFR2 fusion–positive cholangiocarcinoma.
Wainberg Weighs in on Favorable Frontline Activity With NALIRIFOX Regimen in Pancreatic Cancer
July 3rd 2020, 3:15pm
ESMO Gastrointestinal Cancers Congress
Zev. A. Wainberg, MD, discusses findings from a phase 1/2 study of NALIRIFOX in patients with pancreatic ductal adenocarcinoma.
EDP1503 With or Without Pembrolizumab Has Clinical Activity Across Solid Tumors
July 3rd 2020, 3:00pm
ESMO Gastrointestinal Cancers Congress
EDP1503, an investigational monoclonal microbial product, was safe and well-tolerated when administered in combination with pembrolizumab (Keytruda), and mechanistically drove some of the patient responses seen in a phase 1/2 study.
Dr. Yoon on Updated Results of the KEYNOTE-061 Study in Advanced Gastric/GEJ Cancer
July 2nd 2020, 10:00pm
ESMO Gastrointestinal Cancers Congress
Harry H. Yoon, MD, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.
Irinotecan Monotherapy Shows Similar Activity, Improved Safety as Chemo Combo in Advanced Gallbladder Cancer
July 2nd 2020, 9:00pm
ESMO Gastrointestinal Cancers Congress
Irinotecan monotherapy demonstrated similar clinical activity and improved safety compared with capecitabine plus irinotecan in patients with advanced gallbladder cancer, representing a potential second-line treatment for frail patients.
Dr. Ramaswamy on Capecitabine and Irinotecan Monotherapy in Gallbladder Cancer
July 2nd 2020, 6:24pm
ESMO Gastrointestinal Cancers Congress
Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.
Infigratinib Under Investigation in FGFR2-Altered Advanced Cholangiocarcinoma
July 2nd 2020, 6:15pm
ESMO Gastrointestinal Cancers Congress
Ghassan K. Abou-Alfa, MD, discusses the design and aim of the PROOF trial in advanced cholangiocarcinoma.
Dr. Abou-Alfa on Key Eligibility Criteria for the PROOF Trial in Cholangiocarcinoma
July 2nd 2020, 5:50pm
ESMO Gastrointestinal Cancers Congress
Ghassan K. Abou-Alfa, MD, discusses key eligibility criteria for the phase 3 PROOF trial in cholangiocarcinoma.
Maintenance Olaparib Maintains Benefit in Metastatic Pancreatic Cancer, Regardless of Age
July 2nd 2020, 2:45pm
ESMO Gastrointestinal Cancers Congress
The safety and efficacy of maintenance olaparib in patients with BRCA1/2-mutated metastatic pancreatic cancer proved to be consistent irrespective of age, according to results of a subgroup analysis from the pivotal phase 3 POLO trial.
Real-World Data Indicate Favorable Efficacy With Nivolumab in Advanced Gastric Cancer
July 2nd 2020, 2:18pm
ESMO Gastrointestinal Cancers Congress
Yu Sunakawa, MD, PhD, further discusses the early real-world data from the DELIVER trial with nivolumab in patients with gastric/GEJ cancer and provided insight into what future analyses will examine.
Efficacy With Entrectinib in NTRK+ GI Cancers Indicates a Need for More Molecular Testing
July 1st 2020, 10:42pm
ESMO Gastrointestinal Cancers Congress
Manish R. Patel, DO, further discusses next steps for entrectinib, as well as the need for genetic testing to identify uncommon gene rearrangements in GI malignancies.
Durvalumab/Tremelimumab Combo Could Expand Frontline Options in Advanced HCC
July 1st 2020, 9:29pm
ESMO Gastrointestinal Cancers Congress
Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from a study of combination durvalumab and tremelimumab, as well as the clinical need for alternative combination regimens in advanced hepatcellular carcinoma.
Frontline NALIRIFOX Regimen Shows Promising Activity, Tolerability in Pancreatic Cancer
July 1st 2020, 8:57pm
ESMO Gastrointestinal Cancers Congress
The regimen of liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin demonstrated a tolerable safety profile with promising antitumor activity when used as frontline treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Atezolizumab/Bevacizumab Shows Comparable Activity in Older Patients With Advanced HCC
July 1st 2020, 6:24pm
ESMO Gastrointestinal Cancers Congress
The combination of atezolizumab and bevacizumab demonstrated comparable clinical activity and safety versus sorafenib in older and younger patients with previously untreated, unresectable hepatocellular carcinoma.
Dr. Patel on the Role of Entrectinib in Gastrointestinal Malignancies
July 1st 2020, 6:21pm
ESMO Gastrointestinal Cancers Congress
Manish R. Patel, DO, discusses the role of entrectinib in gastrointestinal malignancies.